A study to evaluate the effectiveness safety and tolerability of Ribociclib in Indian women with advanced Breast Cancer.
Not Applicable
Completed
- Conditions
- Health Condition 1: C509- Malignant neoplasm of breast of unspecified site
- Registration Number
- CTRI/2022/04/042230
- Lead Sponsor
- ovartis Healthcare Private Limited
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 410
Inclusion Criteria
1. Greater than equal to 18 years old women 2. HR+ve and HER2-ve aBC diagnosis 3. Received ribociclib plus ET in line with the approved indication with at least one follow-up visit after diagnosis, or death due to any cause
Exclusion Criteria
1. Any patient with prior/current enrollment in an interventional clinical trial for aBC/metastatic BC 2. Patient who has received another CDK4/6 inhibitor in any setting
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method